Memorial Sloan Kettering Cancer Center immunologist Santosha Vardhana describes the cruelest part of cancer immunotherapy in one sentence: the treatment seems to be working for a patient, and then it fades. His laboratory traced part of that fade to a single signalling molecule called MEK, and showed in animal and cell models that switching it off let worn-out T cells go on living and working inside tumours.
The paper, published in the journal Immunity in mid-2026 under first author Tanmana Mitra, is titled “MEK-dependent bioenergetic demand drives terminal CD8 T cell exhaustion”. It has been circulating in science news roundups since its release in July, and it remains a laboratory result, not a clinical one.
MEK as the throttle on T cell fuel use
T cells that meet the same tumour antigen over and over eventually slide into a state called exhaustion. They still sit in the tumour, but they stop multiplying and stop killing efficiently. The textbook explanation was that they run short of energy. The Memorial Sloan Kettering team found the reverse: according to the institution’s own announcement of the work, exhausted cells are metabolically busy, burning large amounts of fuel to manufacture the proteins they use to attack cancer cells.
Mitra described the shift in thinking as moving from a problem of too little energy to one of excessive energy demand. The molecule that sets that demand is MEK. In the preprint version of the study, chronic stimulation of the T cell receptor keeps MEK switched on, which raises nutrient uptake, speeds up protein synthesis through the mTORC1 pathway, drives up the cell’s demand for ATP and lets damaging reactive oxygen species build up in the mitochondria.
Inhibited MEK and the cells that kept working
When the researchers inhibited MEK, the cells behaved more like savers than spenders. Blocking MEK, in the institution’s account, lets cells conserve their resources, and News-Medical’s account quotes him saying the inhibition makes already exhausted cells more conservative, helping them live longer while lowering the pace at which they make the proteins that do the killing.
The treated cells consumed less energy yet proliferated more, a combination OncoDaily’s summary calls counterintuitive. They persisted under the harsh conditions of the tumour, kept progenitor-like features instead of progressing to terminal exhaustion, and held on to their ability to renew themselves. The preprint reports that this restored proliferative capacity in nutrient-poor tumour surroundings, which is the setting where T cells usually fail first.
That trade has a price. Slowing protein production means each cell kills at a lower rate, so the benefit depends on the cells lasting long enough to make up the difference. The MSK team frames MEK as a metabolic checkpoint: a dial between all-out attack and endurance.
Preclinical limits and the path to patients
Every experiment behind this result used animal models and laboratory cell systems. No source consulted reports a survival figure, a tumour-shrinkage percentage or a patient outcome, and the finding that T cells stay alive longer applies to those models only. Vardhana has also cautioned that MEK inhibition will not suit everyone. Tumour size and the number of immune cells available appear to matter, and patients with small tumours and strong immune responses may not need the intervention at all.
One practical point makes the idea attractive to oncologists: MEK inhibitors already exist as approved drugs for other cancers, so the pharmacology is not starting from zero. The authors suggest pairing them with checkpoint inhibitors, CAR-T cell therapy or tumour-infiltrating lymphocyte therapy, all treatments in which T cell burnout limits durability. The Fight Aging commentary describes the finding as showing MEK controls whether exhausted cells conserve fuel or go for broke, and notes that the original paper holds the experimental detail.
The distinction matters for how far the result can be read. Animal models and cultured T cells allow tight control of antigen exposure and drug dose, which is what lets a metabolic mechanism be isolated cleanly. A person’s tumour, with its mixed immune cells, prior treatments and uneven blood supply, is a far noisier setting, and a molecule that spares T cells in one setting can behave differently in the other. The Memorial Sloan Kettering write-up itself stops at calling the findings a potential route, not a demonstrated benefit.
The funding behind the work, listed by the cancer center, includes an NCI K08 Career Development Award, a Burroughs Wellcome Fund Career Award, a V Foundation Scholar Award and the center’s Josie Robertson Investigators program, which places the study in the long-running academic effort to extend immunotherapy responses rather than in a company pipeline.
What remains unanswered is timing. Neither the institution nor the preprint says when in a patient’s course a MEK inhibitor would have to be given, or how to select the people whose tumours would respond, and Vardhana’s group has not announced a trial.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- The NSA says three phone features should be off whenever you aren’t using them
- Hawaii’s magnitude 6.0 Kona earthquake is now a federal major disaster
- Comcast is shutting down its email service, and Xfinity customers must act to keep it
- Invisible volcanic gas at a California ski resort has killed three ski patrollers
